World neurosurgery · 2025
Brain Tissue Oxygen Combined with Intracranial Pressure Monitoring in Patients with Severe Traumatic Brain Injury: An Updated Systematic Review and Pooled Analysis Following the OXY-TC Trial.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chang Yu, Wong Chia-En, Hsu Hao-Hsiang, Chi Kuan-Yu, Lee Jung-Shun, Huang Yen-Ta, Huang Chih-Yuan
Аннотация
BACKGROUND: Severe traumatic brain injury (TBI) is associated with high mortality and long-term disability. Effective TBI management, aimed at minimizing secondary brain damage, requires constant monitoring of intracranial pressure (ICP) with or without brain tissue oxygen pressure (PbtO2). The recent OXY-TC trial suggested that combined ICP + PbtO2 monitoring does not improve the 6-month neurological outcomes, prompting a meta-analysis to reassess the clinical role of PbtO2 monitoring.
METHODS: We conducted a systematic review and meta-analysis by searching the PubMed, Medline, and Cochrane databases for randomized controlled trials and prospective studies on adult severe TBI patients, comparing clinical outcomes of ICP monitoring alone versus ICP + PbtO2 monitoring. Data extraction and quality assessments were performed independently by two reviewers. Meta-analyses were conducted using a random-effects model, focusing on 6-month mortality and favorable functional outcomes.
RESULTS: Six studies met the inclusion criteria. The ICP + PbtO2 group is more likely to have favorable outcomes (odds ratio: 1.39, 95% confidence interval: 1.01-1.92, I2 = 0%) 6 months following TBI. There were no statistically significant differences in the 6-month mortality (odds ratio: 0.75, 95% confidence interval: 0.52-1.10; I2 = 0%).
CONCLUSIONS: Our research findings partially align with the OXY-TC trial regarding the primary endpoint, demonstrating that brain tissue oxygen-guided therapy does not significantly reduce mortality rates in TBI patients 6 months postinjury. However, in contrast to the OXY-TC trial, we observed that the PbtO2 monitoring group showed a significantly higher proportion of favorable outcomes.
METHODS: We conducted a systematic review and meta-analysis by searching the PubMed, Medline, and Cochrane databases for randomized controlled trials and prospective studies on adult severe TBI patients, comparing clinical outcomes of ICP monitoring alone versus ICP + PbtO2 monitoring. Data extraction and quality assessments were performed independently by two reviewers. Meta-analyses were conducted using a random-effects model, focusing on 6-month mortality and favorable functional outcomes.
RESULTS: Six studies met the inclusion criteria. The ICP + PbtO2 group is more likely to have favorable outcomes (odds ratio: 1.39, 95% confidence interval: 1.01-1.92, I2 = 0%) 6 months following TBI. There were no statistically significant differences in the 6-month mortality (odds ratio: 0.75, 95% confidence interval: 0.52-1.10; I2 = 0%).
CONCLUSIONS: Our research findings partially align with the OXY-TC trial regarding the primary endpoint, demonstrating that brain tissue oxygen-guided therapy does not significantly reduce mortality rates in TBI patients 6 months postinjury. However, in contrast to the OXY-TC trial, we observed that the PbtO2 monitoring group showed a significantly higher proportion of favorable outcomes.